P8396
Piperacillin sodium salt
penicillin analog
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C23H26N5NaO7S
CAS 번호:
Molecular Weight:
539.54
UNSPSC Code:
51282423
NACRES:
NA.85
PubChem Substance ID:
EC Number:
261-868-6
Beilstein/REAXYS Number:
5373920
MDL number:
Quality Level
form
powder
solubility
H2O: soluble 50 mg/mL
antibiotic activity spectrum
Gram-negative bacteria, Gram-positive bacteria
mode of action
cell wall synthesis | interferes
storage temp.
2-8°C
SMILES string
[Na+].CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O)c4ccccc4)C(=O)C1=O
InChI
1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1
InChI key
WCMIIGXFCMNQDS-IDYPWDAWSA-M
유사한 제품을 찾으십니까? 방문 제품 비교 안내
General description
Chemical structure: β-lactam
Application
Piperacillin is a semisynthetic, broad-spectrum ureidopenicillin antibiotic. It is derived from ampicillin. It has been used in pharmacokinetic studies in order to optimize antimicrobial therapy in patients with sepsis. It is used to study piperacillin hypersensitivity reactions and to study multidrug-resistant organisms.
Biochem/physiol Actions
Piperacillin inhibits the last stage of bacterial cell wall synthesis by binding to certain penicillin-binding proteins (PBPs), which results in cell lysis. Cell lysis is mediated by bacterial cell wall autolytic enzymes. Piperacillin may interfere with autolysin inhibitors.
Packaging
1g,5g,10g
Other Notes
Keep container tightly closed in a dry and well-ventilated place.Keep in a dry place.
저장 등급
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Zhiping Li et al.
European journal of clinical pharmacology, 69(6), 1223-1233 (2013-01-29)
To develop population pharmacokinetic (PK) models for piperacillin/tazobactam in neonates and infants of less than 2 months of age in order to determine the appropriate dosing regimen and provide a rational basis for the development of preliminary dosing guidelines suitable
João Gonçalves-Pereira et al.
PloS one, 7(11), e49845-e49845 (2012-11-28)
The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients
Jennifer A Pratt et al.
Pediatric blood & cancer, 61(2), 366-368 (2013-09-17)
Neutropenic fever is a common complication of myelosuppressive therapy in pediatric oncology patients. Piperacillin-tazobactam (PIP/TAZO) is a broad spectrum antibiotic used for empiric treatment of neutropenic fever. We describe four cases of suspected PIP/TAZO induced nephrotoxicity occurring in children with
M A Zeitlinger et al.
The Journal of antimicrobial chemotherapy, 56(4), 703-708 (2005-08-27)
Pharmacokinetic (PK)/pharmacodynamic (PD) models have become increasingly important in optimizing antimicrobial therapy. This approach is highly recommended by regulatory authorities intending to force the evaluation of antimicrobial action at the site of infection. Clinical isolates of Pseudomonas aeruginosa and Staphylococcus
S Christian Cheatham et al.
International journal of antimicrobial agents, 41(1), 52-56 (2012-12-12)
The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Fourteen hospitalised patients weighing >120kg received piperacillin/tazobactam 4.5 g every 8 h (q8h) or 6.75 g q8h infused over
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.